# Bioequivalency Study of 600 mg Oxcarbazepine Tablets Under Fasting Conditions

> **NCT00616681** · NA · COMPLETED · sponsor: **Roxane Laboratories** · enrollment: 28 (actual)

## Conditions studied

- Seizures
- Epilepsy

## Interventions

- **DRUG:** Oxcarbazepine

## Key facts

- **NCT ID:** NCT00616681
- **Lead sponsor:** Roxane Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2004-07
- **Final completion:** 2004-07
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00616681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00616681, "Bioequivalency Study of 600 mg Oxcarbazepine Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00616681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*